Article Details
Retrieved on: 2021-08-27 17:26:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NEW YORK – Roche said this week that it will withdraw its immunotherapy atezolizumab (Tecentriq) in combination with nab-paclitaxel as an option for ...
Article found on: www.precisiononcologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here